Want to see GB:IBAI full AI Analyst Report?
IQ-AI (IBAI) AI Stock Analysis
IQ-AI
(LSE:IBAI)
The score is held back primarily by weak financial performance—persistent net losses, a much smaller equity base, and increased leverage—despite improved 2025 cash flow. Technical indicators are comparatively supportive with strong trend/momentum, but valuation remains challenged by negative earnings and no dividend yield data.
IQ-AI (IBAI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 1.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 511.97K
- Price to Earnings (P/E)
- -8.0
- Beta (1Y)
- 0.97
- Revenue Growth
- 15.80%
- EPS Growth
- -66.67%
- Country
- UK
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
IQ-AI Business Overview & Revenue Model
Company Description
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and...
How the Company Makes Money
null
IQ-AI Financial Statement Overview
Summary
Revenue is growing with very strong gross margins (~82% in 2025) and 2025 free cash flow turned positive (~£74k). However, operating profit and net income remain negative, with a net loss around 51% of revenue, and equity has declined materially while leverage stepped up (~0.73x debt-to-equity), keeping the financial risk profile elevated.
Income Statement
34NegativeBalance Sheet
45NeutralCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 810.42K | 788.15K | 750.11K | 609.39K | 535.89K | 521.07K |
| Gross Profit | 661.16K | 646.11K | 687.87K | 482.35K | 534.10K | 504.02K |
| EBITDA | 121.90K | -65.95K | -272.63K | -498.55K | -360.28K | -356.87K |
| Net Income | -237.44K | -400.94K | -327.10K | -623.82K | -511.60K | -501.06K |
Balance Sheet | ||||||
| Total Assets | 1.18M | 1.01M | 929.67K | 720.74K | 1.27M | 1.58M |
| Cash, Cash Equivalents and Short-Term Investments | 49.38K | 112.61K | 53.50K | 138.75K | 313.99K | 728.59K |
| Total Debt | 177.45K | 172.32K | 0 | 0 | 62.20K | 55.41K |
| Total Liabilities | 875.04K | 778.82K | 627.14K | 625.81K | 560.51K | 392.79K |
| Stockholders Equity | 307.72K | 235.30K | 302.53K | 94.92K | 707.07K | 1.19M |
Cash Flow | ||||||
| Free Cash Flow | 153.64K | 74.34K | -136.16K | -175.23K | -414.60K | -345.32K |
| Operating Cash Flow | 153.65K | 74.34K | -136.16K | -96.83K | -374.67K | -288.76K |
| Investing Cash Flow | -176.62K | -255.53K | -308.98K | -78.41K | -39.93K | -56.56K |
| Financing Cash Flow | 0 | 240.30K | 359.89K | 0 | 0 | 595.00K |
IQ-AI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IBAI, the sentiment is Neutral. The current price of 0.80 is below the 20-day moving average (MA) of 0.88, below the 50-day MA of 0.83, and above the 200-day MA of 0.65, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 39.36 is Neutral, neither overbought nor oversold. The STOCH value of 39.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:IBAI.
IQ-AI Peers Comparison
Overall Rating
GB:IXI64Neutral- GB:IBAI51Neutral
GB:GDR49Neutral
GB:COG44Neutral
GB:OBD40Underperform
GB:RENX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:IXI | 64Neutral | GBP 25.73M | -5.99 | -16.18% | ― | 13.04% | 15.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:IBAI | 51Neutral | GBP 1.97M | -8.00 | -87.45% | ― | 15.80% | -66.67% |
| GB:GDR | 49Neutral | GBP 15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:COG | 44Neutral | GBP 15.11M | -9.30 | -54.17% | ― | 11.86% | 23.81% |
| GB:OBD | 40Underperform | GBP 14.45M | -0.27 | -451.74% | ― | 33.37% | 86.41% |
| GB:RENX | 40Underperform | GBP 36.54M | -3.44 | 675.00% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:IBAI | IQ-AI Limited | 0.80 | 0.03 | 3.90% | |
| GB:COG | Cambridge Cognition Holdings | 28.00 | -5.00 | -15.15% | |
| GB:GDR | Genedrive plc | 0.97 | 0.01 | 1.25% | |
| GB:IXI | IXICO plc | 11.75 | 0.25 | 2.17% | |
| GB:OBD | Oxford BioDynamics | 0.11 | -0.21 | -66.56% | |
| GB:RENX | Renalytix Plc OTC | 5.45 | -1.93 | -26.15% |
IQ-AI Corporate Events
Imaging Biometrics strengthens U.S. pipeline and launches IB Vista platform
PositiveImaging Biometrics reported a stronger commercial pipeline in the third quarter, with active talks under way with leading U.S. academic medical centres and health systems in neurology, neurosurgery and cancer care. The company also added two annual I...
Imaging Biometrics Wins Key Health System Deal for Brain Tumor Imaging Software
PositiveImaging Biometrics Limited has secured an annual subscription agreement with a major regional health system for its U.S. subsidiary’s quantitative neuro-oncology imaging software suite, including IB Neuro, IB Delta T1, and IB FTBx. The deal pos...
Imaging Biometrics Wins Major U.S. Hospital Deal for Brain Tumour Software
PositiveImaging Biometrics’ U.S. subsidiary has secured an annual subscription from a major Midwest academic medical centre for IB Clinic, its automated brain tumour imaging platform. The deal will contribute fully to recurring revenue in 2027 and alig...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 02, 2026